Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ExcelFin Acquisition Corp.XFIN · Entity 108733 | Advisory Board Member | October 20, 2021 | October 20, 2021 |
| Humacyte, Inc.HUMA · Entity 6478 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ExcelFin Acquisition Corp.
Report date October 20, 2021 · Filed October 20, 2021
This filing explicitly reported no securities owned.
Humacyte, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.08 · Expires 2036-06-11 | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 0 · Balance 0 F1: The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2022 Filed Jun 13, 2022 16:20 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 8,500 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0001818382-22-000088 · wf-form4_165515158910639.xml · derivative · entry 1 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2032-06-09 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 9, 2023, after which 1/48 of the option will become exercisable on the 9th of each month through June 9, 2026. Read SEC document |
| May 23, 2022 Filed May 25, 2022 10:22 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 10,000 | $4.83 | $48,300.00 |
DisclosureSEC source: 0001818382-22-000051 · wf-form4_165348852456360.xml · nonDerivative · entry 1 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,158,240 Read SEC document |
| December 16, 2021 Filed Dec 16, 2021 19:47 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 75,000 | $9.00 | $675,000.00 |
DisclosureSEC source: 0001104659-21-150679 · tm2135715-2_4seq1.xml · nonDerivative · entry 4 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,161 F5 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.79 to $9.33. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 19:47 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 125,000 | $8.89 | $1,110,625.00 |
DisclosureSEC source: 0001104659-21-150679 · tm2135715-2_4seq1.xml · nonDerivative · entry 3 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,161 F4 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.68 to $9.43. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 19:47 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 76,306 | $9.33 | $711,553.45 |
DisclosureSEC source: 0001104659-21-150679 · tm2135715-2_4seq1.xml · nonDerivative · entry 2 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710,161 F3 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.825 to $9.49. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 19:47 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 23,694 | $9.80 | $232,153.81 |
DisclosureSEC source: 0001104659-21-150679 · tm2135715-2_4seq1.xml · nonDerivative · entry 1 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 786,467 F1 · shares: A portion of this sale is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the purchase by Ayabudge LLC of 1,522,500 shares of the Issuer's common stock on August 26, 2021, at a price per share of $10.00. The Reporting Person has paid the Issuer $71.21, representing the full amount of profit realized in connection with this sale. F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.50 to $10.06. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 15:40 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 8,500 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126716 · tm2130120-4_4seq1.xml · derivative · entry 1 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 1,575 | Not disclosed Strike: $10.28 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 13 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,575 Underlying: Common Stock · 1,575 shares Expires 2030-12-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F5 · derivative.exercise_date: Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 1,312,984 | Not disclosed Strike: $10.28 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 12 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,312,984 Underlying: Common Stock · 1,312,984 shares Expires 2031-01-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F4 · derivative.exercise_date: One-third of the option will vest on each of the three anniversaries after November 9, 2020. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 131,298 | Not disclosed Strike: $6.54 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 11 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 131,298 Underlying: Common Stock · 131,298 shares Expires 2028-04-12 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 262,596 | Not disclosed Strike: $3.44 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 10 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 262,596 Underlying: Common Stock · 262,596 shares Expires 2026-09-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 157,558 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 9 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 157,558 Underlying: Common Stock · 157,558 shares Expires 2026-03-09 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 13,129 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 8 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 13,129 Underlying: Common Stock · 13,129 shares Expires 2025-09-01 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 262,596 | Not disclosed Strike: $1.19 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 7 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 262,596 Underlying: Common Stock · 262,596 shares Expires 2023-11-22 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 17,068 | Not disclosed Strike: $6.54 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 6 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,068 Underlying: Common Stock · 17,068 shares Expires 2028-04-12 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 13,129 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · derivative · entry 5 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,129 Underlying: Common Stock · 13,129 shares Expires 2025-09-01 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 1,522,500 | $10.00 | $15,225,000.00 |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · nonDerivative · entry 3 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ayabudge LLC Disclosed balance after: 20,452,504 Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantCommon Stock | 18,930,004 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · nonDerivative · entry 2 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Ayabudge LLC Disclosed balance after: 18,930,004 F1 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the"Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:14 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantCommon Stock | 1,148,240 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-110543 · tm2125954-24_4seq1.xml · nonDerivative · entry 1 Dougan Brady W · CIK 0001878020 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,148,240 F1 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the"Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.